| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8528134 | Clinical Therapeutics | 2018 | 11 Pages |
Abstract
The use of targeted therapeutics in the treatment of EOC, both as monotherapy and in combination, will continue to expand as more mechanisms of tumorigenesis are identified. Multiple clinical trials of a wide range of targeted therapeutics are currently ongoing. Evidence-based selection of drug targets and appropriate patient populations will allow strategic application of targeted therapeutics.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Monica Hagan MD, John L. MD, PhD,